Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties

被引:59
|
作者
Ulrich, Silvia
Fischler, Manuel
Speich, Rudolf
Popov, Vladimir
Maggiorini, Marco
机构
[1] Univ Zurich Hosp, Dept Internal Med, Div Resp, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Div Crit Care Med, CH-8091 Zurich, Switzerland
[3] Clin Pulm Med & Rehabil, Barmelweid, Switzerland
关键词
chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; pulmonary hemodynamics; pulmonary vascular compliance; vasoreactivity testing;
D O I
10.1378/chest.130.3.841
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are the major classes of pulmonary hypertensive disorders according to the World Health Organization; both lead to right heart failure and death. A better understanding of disease mechanisms has led to the suggestion that the thromboembolic and nonthrombo-embolic types of pulmonary hypertension may share pathophysiologic features. We therefore compared acute vasoreactivity and proximal pulmonary artery compliance in patients with PAH and CTEPH during the initial diagnostic heart catheterization. Methods: Right heart catheterization using a flow-directed Swan-Ganz catheter was performed in patients with CTEPH (n = 22) and PAH (n = 35). Pulmonary hemodynamics were assessed at baseline, during the inhalation of 40 ppm of nitric oxide, and 30 min after the inhalation of 10 mu g of iloprost. To assess the proximal pulmonary artery compliance, the pulse pressure (PP) [systolic - diastolic pressure] and the fractional PIP (PPf) [divided by the mean pressure] were calculated. Results: Both vasodilators produced similar hemodynamic improvement, and the difference between CTEPH and PAH was not significant. The baseline PP and PPf did not vary between the two groups. Conclusion: Patients with PAH and CTEPH show similar acute vasoreactivity to inhaled nitric oxide and iloprost, and have similar pulmonary artery compliance. These findings support the presence of some shared pathophysiologic pathways in both disorders and may lead to therapeutic implications in patients with inoperable CTEPH.
引用
收藏
页码:841 / 846
页数:6
相关论文
共 50 条
  • [21] Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Smukowska-Gorynia, Anna
    Marcinkowska, Justyna
    Chmara, Ewa
    Malaczynska-Rajpold, Katarzyna
    Slawek-Szmyt, Sylwia
    Cieslewicz, Artur
    Janus, Magdalena
    Araszkiewicz, Aleksander
    Jankiewicz, Stanislaw
    Komosa, Anna
    Olasinska-Wisniewska, Anna
    Tomaszewska, Iga
    Mularek-Kubzdela, Tatiana
    RESPIRATION, 2018, 96 (03) : 222 - 230
  • [22] Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Benza, Raymond L.
    Langleben, David
    Hemnes, Anna R.
    Noordegraaf, Anton Vonk
    Rosenkranz, Stephan
    Thenappan, Thenappan
    Hassoun, Paul M.
    Preston, Ioana R.
    Ghio, Stefano
    Badagliacca, Roberto
    Vizza, Carmine D.
    Lang, Irene M.
    Meier, Christian
    Gruenig, Ekkehard
    EUROPEAN RESPIRATORY REVIEW, 2022, 31 (166):
  • [23] Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
    Kirson, Noam Y.
    Birnbaum, Howard G.
    Ivanova, Jasmina I.
    Waldman, Tracy
    Joish, Vijay
    Williamson, Todd
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (09) : 1763 - 1768
  • [24] Quality of Life in pulmonal arterial Hypertension and in chronic thromboembolic pulmonary Hypertension
    Halank, M.
    Speich, R.
    Petkova, D.
    Saxer, S.
    Mueller-Mottet, S.
    Hasler, E.
    Kolditz, M.
    Wilkens, H.
    Ehlken, N.
    Lichtblau, M.
    Egenlauf, B.
    Kaehler, C.
    Lueneburg, N.
    Mertens, D.
    Schulz, U.
    Barner, A.
    Gruenig, E.
    Puhan, M.
    Ulrich, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S126 - S135
  • [25] Diagnostic dilemma in pulmonary arterial hypertension Idiopathic or chronic thromboembolic hypertension?
    Canpolat, U.
    Ozeke, O.
    Yilmaz, S.
    Basar, F. N.
    Cagli, K.
    Golbasi, Z.
    HERZ, 2015, 40 (02) : 338 - 339
  • [26] The Role of Oxygen Challenge in the Assessment of Acute Vasoreactivity in Pulmonary Arterial Hypertension
    Milinic, T.
    Abbott, C.
    Bull, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [27] Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
    Toshner, Mark R.
    Gopalan, Deepa
    Suntharalingam, Jay
    Treacy, Carmen
    Soon, Elaine
    Sheares, Karen K.
    Morrell, Nicholas W.
    Screaton, Nicholas
    Pepke-Zaba, Joanna
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (06): : 610 - 615
  • [28] Predictors of physical activity in pulmonary arterial and chronic thromboembolic pulmonary hypertension
    Saxer, Stephanie
    Lichtblau, Mona
    Berlier, Charlotte
    Hasler, Elisabeth
    Schwarz, Esther
    Ulrich, Silvia
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [29] Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
    Olsson, Karen M.
    Frank, Anika K.
    Hoeper, Marius M.
    Welte, Tobias
    Thomas, Bitter
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [30] Support Experienced by Patients Living with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Ivarsson, Bodil
    Ekmehag, Bjorn
    Sjoberg, Trygve
    HEART LUNG AND CIRCULATION, 2016, 25 (01): : 35 - 40